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To the Editor
We have read with great interest and enjoyed Dr Özkanlı et
al.’s well designed and well written research paper entitled
“Gleason score at the margin can predict biochemical
recurrence after radical prostatectomy, in addition to
preoperative PSA and surgical margin status” in a recent
issue of the journal (2014; 44 (3): 397–402) (1). However,
we have some questions about the study. As we understand,
94 patients were included in your study and these patients
were with pathologic stage T2 and T3 and 34 patients
(36.2%) had positive surgical margins (PSMs). Patients
with node positive disease and who received neoadjuvant or
adjuvant therapy were excluded from the study. We want to
learn more about the neoadjuvant or adjuvant therapy; did
they receive any radiotherapy (RT) or androgen deprivation
therapies (ADT)? We agree that high preoperative PSA
levels, PSMs, and high Gleason score (GS) have a poor
prognostic impact, and they are related with a higher rate
of biochemical recurrence (BCR). Close follow-up of these
patients is recommended.
As is well known, surgery, RT, and ADT are treatment
choices in prostate cancer. In approximately two-thirds of
men, radical prostatectomy (RP) constituted a cure, but
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up to one-third of patients manifested recurrent disease
(2,3). Recurrence risk is greater among men with adverse
pathology such as positive surgical margins, higher
GS, extraprostatic extension (EPE), and seminal vesicle
invasion (SVI). Recurrence rates in post-RP patients with
adverse pathology may be greater than 60% at 5 years and
>60% in high-risk patients who underwent RP only (4–6).
Radiotherapy as an adjuvant therapy reduces the risk of
BCR, local recurrence, clinical progression of cancer, and the
need for subsequent salvage therapies. Adjuvant RT (ART)
is the administration of RT postprostatectomy to patients at
a higher risk of recurrence because of adverse pathological
features prior to evidence of disease recurrence. Salvage
RT (SRT) is the administration of RT to the prostatic bed
and possibly to the surrounding tissues, including lymph
nodes, in the patient with PSA recurrence after surgery but
no evidence of distant metastatic disease (4).
In the guidelines, ADT is regarded as the neoadjuvant
therapy, with RT or adjuvant therapy (7).
In our particular conclusion, 48.9% BCR at two years is
significant and RT should be added as an adjuvant therapy
after the RP.
With our best regards,
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Reply to Letter to the Editor: “The role of radiotherapy after radical prostatectomy” by Aktan and Koç.
To the Editor:
We would like to thank Aktan and Koç for their interest in
our recent study entitled “Gleason score at the margin can
predict biochemical recurrence after radical prostatectomy,
in addition to preoperative PSA and surgical margin
status” (1).
Because we were interested in the risk of recurrence,
all patients who had undergone adjuvant therapy
(radiotherapy or hormonal treatment) before biochemical
recurrence were excluded as in previous studies (2,3). The
patients with biochemical recurrence (PSA ≥0.2 ng/mL
at least two measurements) after radical prostatectomy
were treated by radiotherapy and/or hormonal treatment
according to risk factors including preoperative serum
PSA, clinical stage, Gleason score, and pathological stage
(level of extraprostatic extension, seminal vesicle invasion)
in addition to surgical margin positivity (SMP).
The reported overall rates of SMP vary extremely,
reflecting differences in specimen processing, diligence of
the pathologist in examining the tissue, patient selection,

and surgical technique. The reported rate of SMP ranges
from 11% to 37% (4).
For details regarding the patient population, 94 patients
who underwent radical prostatectomy between 2001 and
2010 with at least 2-year follow-up were included. The
mean and median follow-up times were more than 5
years. Furthermore, radical prostatectomy was performed
by four surgeons with different surgical experience. This
limitation of our study may be another reason for the
high rate of surgical margin positivity and biochemical
recurrence.
Although our results are promising, several limitations
such as the sample size, single-center experience,
and short follow-up may apply to our analyses. To
date no preoperative or postoperative biomarker or
histopathological finding has been shown to predict the
precise probability of biochemical recurrence after radical
prostatectomy. Our recent study suggests that Gleason
score at the surgical margin may have an independent
prognostic role for predicting biochemical recurrence
after radical prostatectomy.
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